During the last session, Cellectar Biosciences Inc (NASDAQ:CLRB)’s traded shares were 1.98 million, with the beta value of the company hitting 0.52. At the end of the trading day, the stock’s price was $0.37, reflecting an intraday gain of 4.01% or $0.02. The 52-week high for the CLRB share is $3.15, that puts it down -751.35 from that peak though still a striking 40.54% gain since the share price plummeted to a 52-week low of $0.22. The company’s market capitalization is $16.84M, and the average intraday trading volume over the past 10 days was 9.07 million shares, and the average trade volume was 11.81 million shares over the past three months.
Cellectar Biosciences Inc (CLRB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. CLRB has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it.
Cellectar Biosciences Inc (NASDAQ:CLRB) trade information
Cellectar Biosciences Inc (CLRB) registered a 4.01% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 4.01% in intraday trading to $0.37, hitting a weekly high. The stock’s 5-day price performance is -14.36%, and it has moved by 43.05% in 30 days. Based on these gigs, the overall price performance for the year is -88.65%. The short interest in Cellectar Biosciences Inc (NASDAQ:CLRB) is 1.45 million shares and it means that shorts have 1.86 day(s) to cover.
The consensus price target of analysts on Wall Street is $12, which implies an increase of 96.92% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $12 and $12 respectively. As a result, CLRB is trading at a discount of -3143.24% off the target high and -3143.24% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 40.27%. While earnings are projected to return 55.21% in 2025, the next five years will return 24.38% per annum.
CLRB Dividends
Cellectar Biosciences Inc is due to release its next quarterly earnings on 2025-May-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cellectar Biosciences Inc (NASDAQ:CLRB)’s Major holders
Cellectar Biosciences Inc insiders own 1.71% of total outstanding shares while institutional holders control 12.42%, with the float percentage being 12.63%. AIGH CAPITAL MANAGEMENT LLC is the largest shareholder of the company, while 36.0 institutions own stock in it. As of 2024-06-30, the company held over 3.04 million shares (or 8.4764% of all shares), a total value of $6.86 million in shares.
The next largest institutional holding, with 2.71 million shares, is of ROSALIND ADVISORS, INC.’s that is approximately 7.5535% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.76 million.
